Recombinant DNA Technology Market Research Report: By Product (Medical, Non-Medical), Component (Expression System, Cloning Vector), Application (Food & Agriculture, Health & Disease), End-User (Biotechnology Companies, Pharmaceuticals) – Forecast to 2027
ID: MRFR/LS/4389-HCR | February 2021 | Region: Global | 100 pages
Market Scenario
The recombinant DNA technology is a process that manipulates and alters the DNA sequences, resulting in a genetically modified organism and product. These genetically modified products or organisms have superior or specific ability such as resistance to certain chemicals, high productivity, and survival abilities in harsh conditions (GM crops).
The recombinant DNA technology has a practical application of biotechnology in the fields of applied immunology, genomics, diagnostic tools, and development of pharmaceutical therapeutics. There are numerous biological methods used to create a recombinant DNA. The treatment was developed for leukemia disorder, in conjugation between the Novartis Corp and the University of Pennsylvania.
Factors such as the commercial success of the recombinant DNA technology in the biopharmaceutical industry, the increasing adoption of genetically modified crops and biopesticides, and the increasing burden of chronic diseases are driving the growth of the market. Moreover, the increasing need to improve the recombinant protein production capacity and the presence of robust biopharmaceuticals pipeline are increasing the demand for effective therapeutics for disease treatment.
Presently, the genetic testing market is majorly spread in Western Europe and North American. There are vast opportunities for the companies and service providers to make the tests affordable and enter the untapped regions of the world with a great scope of expanding.
The global recombinant DNA technology market is expected to grow at a CAGR of approximately 6.9% during the forecast period, 2017–2023.
Intended Audience
- Recombinant DNA Technology Test Kit Suppliers
- Recombinant DNA Technology Test Kit Manufacturers
- Research and Development (R&D) Companies
- Medical Research Laboratories
- Academic Medical Institutes and Universities
Figure 1: - Global Recombinant DNA Technology Market Share, by Region
Segmentation
The global recombinant DNA technology market is segmented on the basis of product, component, application, and end-user.
On the basis of product, the global recombinant DNA technology market is segmented into medical, non-medical, and others. The medical segment is divided into therapeutic agents, human proteins, and vaccines. The non-medical segment is divided into biotech crops, specialty chemicals, and others.
On the basis of component, the global recombinant DNA technology market is segmented into expression system, cloning vector, and others. The expression system segment is divided into mammalian, bacteria, yeast, baculovirus/insect, and others. The cloning vector segment is divided into plasmid, phage, cosmid, Bacterial Artificial Chromosome (BAC), Yeast Artificial Chromosome (YAC), and Human Artificial Chromosome (HAC).
On the basis of application, the global recombinant DNA technology market is segmented into food and agriculture, health and disease, environment, and others.
On the basis of end-user, the global recombinant DNA technology market is segmented into biotechnology companies, academic and government research institutes, pharmaceuticals, and others.
Research Methodology
Sources: Annual reports, Press release, White paper, and Company presentation
Regional Analysis
The global recombinant DNA technology market is segmented into the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas contributes a major share to the recombinant DNA technology market owing to the widespread successful applications of this technique in veterinary products’ development, genetically modified crops’ development, biopesticides’ and biofuels’ production, and gene therapy. All these factors are expected to spur the adoption of this technology throughout the forecast period.
The European market holds the second largest share of the global recombinant DNA technology market owing to the increasing investments by hospital facilities and by the government for better healthcare. The growing collaborations and partnerships, the low cost of sequencing, and the increasing adoption of NGS procedure by research laboratories are driving the growth of this market.
The Asia Pacific region is expected to witness a rapid growth rate over the forecast period. Countries such as India and China are expected to support the growth of Asia Pacific owing to the increasing government funding for research and development. Moreover, conducting clinical trials in Asian countries such as India are relatively less costly in comparison with the western countries. This has resulted in the migration of several global biopharmaceutical developers towards this region.
The Middle East and Africa are also expected to show healthy growth in the coming five years. There are some factors affecting the growth of the recombinant DNA technology in the Middle East such as lack of knowledge of genetic diseases and disorders, weak health care and research infrastructure, traditional healthcare practices, limited availability of products and services, and cost of the tests.
Key Players
Some of the key players in the global recombinant DNA technology market are F. Hoffmann-La Roche Ltd (Switzerland), Profacgen (U.S.), Amgen Inc. (U.S.), Novartis AG (Switzerland), Genscript Biotech (U.S.), Pfizer Inc. (U.S.), Novo Nordisk A/S (Denmark), Eli Lilly and Company (U.S.), Sanofi S.A. (France), Merck & Co., Inc. (U.S.), Biogen Inc. (U.S.), Biocon Limited (India), GlaxoSmithKline plc (UK), New England Biolabs (U.S.), Cibus (U.S.), Monsanto Company (U.S.), Horizon Discovery Group PLC (U.S.), Boehringer Ingelheim (Germany), and others.
Frequently Asked Questions (FAQ) :
Recombinant DNA technology is a process that manipulates and alters the DNA sequences, resulting in a genetically modified organism.
Recombinant DNA Technology Market is expected to exhibit a strong 6.9% CAGR over the forecast period from 2017 to 2023.
Growing demand for recombinant DNA technology in therapeutic applications is a major driver for the market.
Americas hold the dominant share in the global Recombinant DNA Technology Market.
Leading players in the Recombinant DNA Technology Market include Novartis, Profacgen, and Amgen, among others.
TABLE OF CONTENT
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. Global Recombinant DNA Technology Market, by Product
6.1 Introduction
6.2 Medical
6.2.1 Market Estimates & Forecast, 2020-2027
6.2.2 Therapeutic Agent
6.2.2.1 Market Estimates & Forecast, 2020-2027
6.2.3 Human Protein
6.2.3.1 Market Estimates & Forecast, 2020-2027
6.2.4 Vaccine
6.2.4.1 Market Estimates & Forecast, 2020-2027
6.3 Non-Medical
6.3.1 Market Estimates & Forecast, 2020-2027
6.3.2 Biotech Crops
6.3.2.1 Market Estimates & Forecast, 2020-2027
6.3.3 Specialty Chemicals
6.3.3.1 Market Estimates & Forecast, 2020-2027
6.3.4 Others
6.3.4.1 Market Estimates & Forecast, 2020-2027
6.4 Others
Chapter 7. Global Recombinant DNA Technology Market, by Component
7.1 Introduction
7.2 Expression System
7.2.1 Market Estimates & Forecast, 2020-2027
7.2.2 Mammalian
7.2.2.1 Market Estimates & Forecast, 2020-2027
7.2.3 Bacteria
7.2.3.1 Market Estimates & Forecast, 2020-2027
7.2.4 Yeast
7.2.4.1 Market Estimates & Forecast, 2020-2027
7.2.4 BaculovirU.S./Insect
7.2.4.1 Market Estimates & Forecast, 2020-2027
7.2.5 Others
7.2.5.1 Market Estimates & Forecast, 2020-2027
7.3 Cloning Vector
7.3.1 Market Estimates & Forecast, 2020-2027
7.3.2 Plasmid
7.3.2.1 Market Estimates & Forecast, 2020-2027
7.3.3 Phage
7.3.3.1 Market Estimates & Forecast, 2020-2027
7.3.4 Cosmid
7.3.4.1 Market Estimates & Forecast, 2020-2027
7.3.5 Bacterial Artificial Chromosome (BAC)
7.3.5.1 Market Estimates & Forecast, 2020-2027
7.3.6 Yeast Artificial Chromosome (YAC)
7.3.6.1 Market Estimates & Forecast, 2020-2027
7.3.7 Human Artificial Chromosome (HAC).
7.3.7.1 Market Estimates & Forecast, 2020-2027
7.4 Others
Chapter 8. Global Recombinant DNA Technology Market, by Application
8.1 Introduction
8.2 Food & Agriculture
8.2.1 Market Estimates & Forecast, 2020-2027
8.3 Health & Disease
8.3.1 Market Estimates & Forecast, 2020-2027
8.4 Environment
8.4.1 Market Estimates & Forecast, 2020-2027
8.5 Others
Chapter 9. Global Recombinant DNA Technology Market, by End-U.S.er
9.1 Introduction
9.2 Biotechnology Companies
9.2.1 Market Estimates & Forecast, 2020-2027
9.3 Academic & Government Research Institutes
9.3.1 Market Estimates & Forecast, 2020-2027
9.4 Pharmaceuticals
9.4.1 Market Estimates & Forecast, 2020-2027
9.5 Others
Chapter .8 Global Recombinant DNA Technology Market, by Region
8.1 Introduction
8.2 Americas
8.2.1 North America
8.2.1.1 U.S.
8.2.1.1 Canada
8.2.2 South America
8.3 Europe
8.3.1 Western Europe
8.3.1.1 Germany
8.3.1.2 France
8.3.1.3 Italy
8.3.1.4 Spain
8.3.1.5 U.K.
8.3.1.6 Rest of Western Europe
8.3.2 Eastern Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 Republic of Korea
8.4.6 Rest of Asia Pacific
8.5 The Middle East & Africa
8.5.1 United Arab Emirates
8.5.2 Saudi Arabia
8.5.3 Oman
8.5.4 Kuwait
8.5.5 Qatar
8.5.6 Rest of the Middle East & Africa
Chapter 9 Company Landscape
9.1 Introduction
9.2 Market Share Analysis
9.3 Key Development & Strategies
9.3.1 Key Developments
Chapter 10 Company Profiles
10.1 F. Hoffmann-La Roche Ltd
10.1.1 Company Overview
10.1.2 Product Overview
10.1.3 Financials
10.1.4 SWOT Analysis
10.2 Profacgen
10.2.1 Company Overview
10.2.2 Product Overview
10.2.3 Financial Overview
10.2.4 Key Developments
10.2.5 SWOT Analysis
10.3 Amgen Inc.
10.3.1 Company Overview
10.3.2 Product Overview
10.3.3 Financial Overview
10.3.4 Key Development
10.3.5 SWOT Analysis
10.4 Novartis AG
10.4.1 Company Overview
10.4.2 Product/Business Segment Overview
10.4.3 Financial Overview
10.4.4 Key Development
10.4.5 SWOT Analysis
10.5 Genscript Biotech
10.5.1 Company Overview
10.5.2 Product Overview
10.5.3 Financial overview
10.5.4 Key Developments
10.6 Pfizer Inc.
10.6.1 Company Overview
10.6.2 Product Overview
10.6.3 Financial Overview
10.6.4 Key Developments
10.7 Novo Nordisk A/S
10.7.1 Overview
10.7.2 Product Overview
10.7.3 Financials
10.7.4 Key Developments
10.7.5 SWOT Analysis
10.8 Eli Lilly and Company
10.8.1 Company Overview
10.8.2 Product/Business Segment Overview
10.8.3 Financial Overview
10.8.4 Key Development
10.8.5 SWOT Analysis
10.9 Sanofi S.A.
10.9.1 Company Overview
10.9.2 Product Overview
10.9.3 Financial overview
10.9.4 Key Developments
10.10 Merck & Co., Inc.
10.10.1 Company Overview
10.10.2 Product Overview
10.10.3 Financial overview
10.10.4 Key Developments
10.11 Biogen Inc.
10.11.1 Company Overview
10.11.2 Product Overview
10.11.3 Financial overview
10.11.4 Key Developments
10.12 Others
Chapter 17 MRFR Conclusion
11.1 Key Findings
11.1.1 From CEO’s View Point
11.1.2 Unmet Needs of the Market
11.2 Key Companies to Watch
11.3 Prediction of the Pharmaceutical Industry
Chapter 12 Appendix
LIST OF TABLES
Table 1 Recombinant DNA technology Industry Synopsis, 2020-2027
Table 2 Recombinant DNA Technology Market Estimates & Forecast, 2020-2027, (USD Million)
Table 3 Recombinant DNA Technology Market, by Region, 2020-2027, (USD Million)
Table 4 Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)
Table 5 Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)
Table 6 Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)
Table 7 Recombinant DNA Technology Market, by End-U.S.er, 2020-2027, (USD Million)
Table 8 North America Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)
Table 9 North America Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)
Table 10 North America Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)
Table 11 North America Recombinant DNA Technology Market, by End-User, 2020-2027, (USD Million)
Table 12 U.S. Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)
Table 13 U.S. Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)
Table 14 U.S. Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)
Table 15 U.S. Recombinant DNA Technology Market, by End-User, 2020-2027, (USD Million)
Table 16 Canada Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)
Table 17 Canada Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)
Table 18 Canada Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)
Table 19 Canada Recombinant DNA Technology Market, by End-User, 2020-2027, (USD Million)
Table 20 South America Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)
Table 21 South America Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)
Table 22 South America Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)
Table 23 South America Recombinant DNA Technology Market, by End-User, 2020-2027, (USD Million)
Table 24 Europe Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)
Table 25 Europe Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)
Table 26 Europe Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)
Table 27 Europe Recombinant DNA Technology Market, by End-User, 2020-2027, (USD Million)
Table 28 Western Europe Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)
Table 29 Western Europe Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)
Table 30 Western Europe Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)
Table 31 Western Europe Recombinant DNA Technology Market, by End-User, 2020-2027, (USD Million)
Table 32 Eastern Europe Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)
Table 33 Eastern Europe Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)
Table 34 Eastern Europe Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)
Table 35 Eastern Europe Recombinant DNA Technology Market, by End-User, 2020-2027, (USD Million)
Table 36 Asia Pacific Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)
Table 37 Asia Pacific Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)
Table 38 Asia Pacific Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)
Table 39 Asia Pacific Recombinant DNA Technology Market, by End-User, 2020-2027, (USD Million)
Table 40 The Middle East & Africa Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)
Table 41 The Middle East & Africa Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)
Table 42 The Middle East & Africa Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)
Table 43 The Middle East & Africa Recombinant DNA Technology Market, by End-User, 2020-2027, (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation of the Recombinant DNA Technology Market
Figure 3 Segmentation Market Dynamics for the Recombinant DNA Technology Market
Figure 4 Global Recombinant DNA Technology Market Share, by Product 2020
Figure 5 Global Recombinant DNA Technology Market Share, by Component 2020
Figure 6 Global Recombinant DNA Technology Market Share, by Application 2020
Figure 7 Global Recombinant DNA Technology Market Share, by End-User2020
Figure 8 Global Recombinant DNA Technology Market Share, by Region, 2020
Figure 9 Americas Recombinant DNA Technology Market Share, by Country, 2020
Figure 10 Europe Recombinant DNA Technology Market Share, by Country, 2020
Figure 11 Asia Pacific Recombinant DNA Technology Market Share, by Country, 2020
Figure 12 Middle East & Africa Recombinant DNA Technology Market Share, by Country, 2020
Figure 13 Global Recombinant DNA Technology Market: Company Share Analysis, 2020 (%)
Figure 14 F. Hoffmann-La Roche Ltd: Key Financials
Figure 15 F. Hoffmann-La Roche Ltd: Segmental Revenue
Figure 16 F. Hoffmann-La Roche Ltd: Geographical Revenue
Figure 17 Profacgen: Key Financials
Figure 18 Profacgen: Segmental Revenue
Figure 19 Profacgen: Geographical Revenue
Figure 20 Amgen Inc.: Key Financials
Figure 21 Amgen Inc.: Segmental Revenue
Figure 22 Amgen Inc.: Geographical Revenue
Figure 23 Novartis AG: Key Financials
Figure 24 Novartis AG: Segmental Revenue
Figure 25 Novartis AG: Geographical Revenue
Figure 26 Genscript Biotech: Key Financials
Figure 27 Genscript Biotech: Segmental Revenue
Figure 28 Genscript Biotech: Geographical Revenue
Figure 29 Pfizer Inc.: Key Financials
Figure 30 Pfizer Inc.: Segmental Revenue
Figure 31 Pfizer Inc.: Geographical Revenue
Figure 32 Novo Nordisk A/S: Key Financials
Figure 33 Novo Nordisk A/S: Segmental Revenue
Figure 34 Novo Nordisk A/S: Geographical Revenue
Figure 35 Eli Lilly and Company: Key Financials
Figure 36 Eli Lilly and Company: Segmental Revenue
Figure 37 Eli Lilly and Company: Geographical Revenue
